Back

Real-world insights into mavacamten use for obstructive hypertrophic cardiomyopathy: symptomatic improvement before gradient reduction?

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (1) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Alexandros Kasiakogias

Hippokration General Hospital, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Review of variants of uncertain significance in hypertrophic cardiomyopathy: a single-center multi-ethnic population experience
Doctor B. Chung (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
Understanding the patient burden in transthyretin cardiac amyloidosis is significantly improved with continuing medical education
Doctor C. Rohani-Montez (London, GB)
Abstract Slides Video
Presentation thumbnail
Investigation of the prevalence of cardiac amyloidosis among patients with echocardiographically verified myocardial hypertrophy of unknown etiology
Doctor N. Gataric (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Diagnostic performance of right ventricle wall thickness, strain, and their ratio in differentiating Fabry cardiomyopathy from wild-type transthyretin cardiac amyloidosis
Doctor E. Mata (Creixomil, PT)
Abstract Slides Video
Presentation thumbnail
Change of 3D echocardiographic parameters in obstructive hypertrophic cardiomyopathy during mavacamten treatment
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (1)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Evaluation of clinical need, effectiveness, and safety of the first myosin inhibitor mavacamten in real world patients
thumbnail
Congress Presentation
Evaluation of cardiac MRI parameters during mavacamten treatment in obstructive hypertrophic cardiomyopathy: three- and six-month results
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources